GNLX Insider Trading

Insider Ownership Percentage: 9.30%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $1,259,755.94

Genelux Insider Trading History Chart

This chart shows the insider buying and selling history at Genelux by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$4M-$2M$0$2M$4MTotal Insider BuyingTotal Insider Selling

Genelux Share Price & Price History

Current Price: $2.46
Price Change: Price Increase of +0.12 (5.13%)
As of 04/11/2025 05:00 PM ET

This chart shows the closing price history over time for GNLX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$2.46Closing price on 04/11/25:

SEC Filings (Institutional Ownership Changes) for Genelux (NASDAQ:GNLX)

37.33% of Genelux stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at GNLX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$420kbought$1.23MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$4M-$2M$0$2M$4MTotal InflowsTotal Outflows
Genelux logo
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Read More on Genelux

Today's Range

Now: $2.46
Low: $2.21
High: $2.48

50 Day Range

MA: $3.77
Low: $2.08
High: $5.66

52 Week Range

Now: $2.46
Low: $1.60
High: $5.89

Volume

183,605 shs

Average Volume

211,079 shs

Market Capitalization

$85.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Genelux?

Genelux's top insider shareholders include:
  1. Aladar Szalay (Major Shareholder)
  2. John Thomas (Director)
  3. Yong Yu (VP)
  4. James L Tyree (Director)
  5. Sean Ryder (General Counsel)
  6. Caroline Jewett (Insider)
  7. Thomas Zindrick (CEO)
  8. John W Smither (Director)
  9. Joseph Cappello (VP)
  10. Doug Samuelson (CFO)
Learn More about top insider investors at Genelux.